17,21-二羟基孕甾-4,9(11)-二烯-3,20-二酮 | 10184-70-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 17,21-二羟基孕甾-4,9(11)-二烯-3,20-二酮
• 中文别名: 阿奈可他
• 英文名称: Anecortave
• 英文别名: (8S,10S,13S,14S,17R)-17-hydroxy-17-(2-hydroxy-acetyl)-10,13-dimethyl-1,2,6,7,8,10,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one；(10S,13S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one；17α,21-dihydroxypregna-4,9(11)-diene-3,20-dione；pregna-4,9(11)-diene-17α,21-diol-3,20-dione；pregnadiene-4,9(11) diol-17α,21 dione-3,20；Δ⁹-cortexolone；(8S,10S,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one
• CAS: 10184-70-0
• 化学式: C₂₁H₂₈O₄
• 分子量: 344.451
• InChiKey: BCFCRXOJOFDUMZ-ONKRVSLGSA-N

物化性质

• 熔点：
  231-233 °C(Solv: tetrahydrofuran (109-99-9))
• 沸点：
  540.4±50.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO（微溶、超声处理）、甲醇（微溶、加热）

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  17,21-二羟基孕甾-4,9(11)-二烯-3,20-二酮 在 manganese(IV) oxide 作用下， 以 氯仿 为溶剂， 反应 4.0h， 以72.6%的产率得到雄甾-4,9(11)-二烯-3,17-二酮
  参考文献：
  名称：

  Improved method of oxidative cleavage of the dihydroxyacetone side chain in corticosteroids

  摘要：

  DOI：

  10.1007/bf00765254
• 作为产物：
  描述：

  Nicotinic acid (8S,9R,10S,13S,14S,17R)-17-(2-acetoxy-acetyl)-9-chloro-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester 在 silver tetrafluoroborate 、 potassium carbonate 作用下， 以 甲醇 、 丙酮 为溶剂， 生成 17,21-二羟基孕甾-4,9(11)-二烯-3,20-二酮
  参考文献：
  名称：

  Selective steroid chlorinations directed by attached pyridine ester templates

  摘要：

  DOI：

  10.1021/ja00246a058

文献信息

• 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents
  申请人：Cassiopea S.P.A.

  公开号：US09211295B2

  公开（公告）日：2015-12-15

  17α,21-Dihydroxypregna-4,9(11)-diene-3,20-dione and 17α,21-dihydroxypregna-4-ene-3,20-dione 17 and/or 21 esters having remarkable antiandrogenic activity are provided, along with methods of using these compounds and processes for their preparation.

  提供具有显著抗雄激素活性的17α,21-二羟孕甾-4,9(11)-二烯-3,20-二酮和17α,21-二羟孕甾-4-烯-3,20-二酮17和/或21酯，以及使用这些化合物的方法和它们的制备过程。
• Direct organocatalytic stereoselective transfer hydrogenation of conjugated olefins of steroids
  作者：Dhevalapally B. Ramachary、Rajasekar Sakthidevi、P. Srinivasa Reddy

  DOI：10.1039/c3ra41519h

  日期：——

  catalyst 1b·D-CSA is mild enough to activate the various chiral cyclic enones through iminium ion formation during the organocatalytic transfer hydrogenations with Hantzsch ester 2a as a hydrogen source. Further, clear evidence for the selective formation of intermediate iminium species [I]+ have been characterized through on-line monitoring of controlled experiments by NMR and ESI-HRMS analyses.

  通过动力学控制和有机催化的顺-选择性转移氢化已成功地证明了各种类固醇的烯酮官能团的还原。在此，已经报道了通过有机催化的许多5β-类固醇的非对映选择性合成，其具有广泛的医学和药学应用。机理研究和产物的选择性清楚地表明，催化剂1b · D -CSA足够温和，可以在以汉茨sch酸酯2a为氢源的有机催化转移加氢过程中通过亚胺离子的形成来活化各种手性环状烯酮。此外，有明确的证据表明可以选择性地形成中间亚胺鎓类物质[ I] +通过NMR和ESI-HRMS分析对受控实验进行在线监测来表征。
• [EN] 2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTALMIC DISEASES<br/>[FR] COMPOSES DE 2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDES EN TANT QU'INHIBITEURS DE PROTEINES KINASES UTILES POUR LE TRAITEMENT DE MALADIES OPHTALMIQUES
  申请人：PFIZER

  公开号：WO2004056806A1

  公开（公告）日：2004-07-08

  Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma,rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  描述了可以调节和/或抑制眼科疾病和某些蛋白激酶活性的吲哚唑化合物。这些化合物和含有它们的药物组合物能够介导酪氨酸激酶信号传导，从而调节和/或抑制不需要的细胞增殖。该发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效剂量来治疗眼科疾病和癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣。
• HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS
  申请人：Ripple Therapeutics Corporation

  公开号：US20210347809A1

  公开（公告）日：2021-11-11

  Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and/or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders.

  本文描述了可加工的组合物，其中至少包含一个可在其自由形式下加工的成分。本文还描述了用于治疗眼部疾病或障碍的组合物和方法，包括青光眼、眼睑炎、眼部炎症、糖尿病性黄斑水肿、后部炎症、前部炎症、黄斑变性（如湿性黄斑变性（AMD）或干性AMD）、白内障手术后和视网膜静脉阻塞。所述组合物和方法包括表现出抗炎活性、降低眼内压力（IOP）和/或其他理想活性的类固醇和前列腺素。将所述组合物注射到眼中可为患有眼部障碍的患者提供治疗益处。
• Conveniently implantable sustained release drug compositions
  申请人：Wong G. Vernon

  公开号：US20060073182A1

  公开（公告）日：2006-04-06

  This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.

  本发明提供了生物相容性和可生物降解的可注射液体、可植入固体和可注射凝胶制药配方，用于治疗系统性和局部疾病状态。